Clinical characteristics and outcomes of candidates for second-line therapy, including regorafenib and ramucirumab, for advanced hepatocellular carcinoma after sorafenib treatment.

Teiji KuzuyaMasatoshi IshigamiTakanori ItoYoji IshizuTakashi HondaTetsuya IshikawaYoshiki HirookaMitsuhiro Fujishiro

Published in: Hepatology research : the official journal of the Japan Society of Hepatology (2019)

Not all patients refractory to sorafenib were candidates for second-line therapy. A Child-Pugh score of A5 at sorafenib initiation was an important and favorable factor related to eligibility for second-line therapy and good outcomes.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
mental health
prognostic factors
glycemic control